Morgan Stanley
AXNX

Morgan Stanley’s Axonics, Inc. Common Stock AXNX Stock Holding History

Morgan Stanley’s Portfolio AXNX Stock Details AXNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-287,128
Closed -$20M – 8185
2024
Q3 		$20M Buy
287,128
+64,297
+29% +$4.41M ﹤0.01% 2809
2024
Q2 		$15M Sell
222,831
-92,758
-29% -$6.25M ﹤0.01% 2974
2024
Q1 		$21.8M Buy
315,589
+28,614
+10% +$1.93M ﹤0.01% 2603
2023
Q4 		$17.9M Buy
286,975
+74,320
+35% +$4.16M ﹤0.01% 2809
2023
Q3 		$11.9M Sell
212,655
-141,207
-40% -$7.94M ﹤0.01% 2959
2023
Q2 		$17.9M Sell
353,862
-144,809
-29% -$7.7M ﹤0.01% 2591
2023
Q1 		$27.2M Buy
498,671
+142,648
+40% +$8.33M ﹤0.01% 2103
2022
Q4 		$22.3M Buy
356,023
+90,287
+34% +$5.99M ﹤0.01% 2232
2022
Q3 		$18.7M Buy
265,736
+26,761
+11% +$1.85M ﹤0.01% 2256
2022
Q2 		$13.5M Buy
238,975
+170,589
+249% +$9.35M ﹤0.01% 2729
2022
Q1 		$4.28M Sell
68,386
-275,893
-80% -$14.9M ﹤0.01% 3846
2021
Q4 		$19.3M Buy
344,279
+159,123
+86% +$9.72M ﹤0.01% 2199
2021
Q3 		$12.1M Sell
185,156
-4,771
-3% -$326K ﹤0.01% 2673
2021
Q2 		$12M Buy
189,927
+110,106
+138% +$6.5M ﹤0.01% 2775
2021
Q1 		$4.78M Sell
79,821
-26,408
-25% -$1.44M ﹤0.01% 3463
2020
Q4 		$5.3M Buy
106,229
+4,456
+4% +$209K ﹤0.01% 3196
2020
Q3 		$5.2M Buy
101,773
+38,103
+60% +$1.59M ﹤0.01% 2679
2020
Q2 		$2.23M Buy
63,670
+6,614
+12% +$228K ﹤0.01% 3497
2020
Q1 		$1.45M Sell
57,056
-23,840
-29% -$709K ﹤0.01% 3642
2019
Q4 		$2.24M Buy
80,896
+30,312
+60% +$723K ﹤0.01% 3947
2019
Q3 		$1.36M Buy
50,584
+18,068
+56% +$629K ﹤0.01% 4096
2019
Q2 		$1.33M Buy
32,516
+17,352
+114% +$488K ﹤0.01% 4058
2019
Q1 		$364K Buy
15,164
+1,444
+11% +$26.2K ﹤0.01% 4740
2018
Q4 		$207K Buy
+13,720
New +$204K ﹤0.01% 5274

Other funds holding AXNX

TCA
Taconic Capital Advisors New York $212M AUM 100.15% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Morgan Stanley's AXNX Position: Q4 2024 in Review

Morgan Stanley sold out of Axonics, Inc. Common Stock (AXNX) in Q4 2024, closing a stake of 287,128 shares — an estimated $20M sold.

Morgan Stanley first reported a position in AXNX in Q4 2018 and held it in 24 quarters. The position peaked at $27.2M in Q1 2023. 2 funds tracked by Wall St. Rank hold AXNX as of Q4 2024.

  • Morgan Stanley reported no remaining Axonics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Morgan Stanley sold 287,128 Axonics, Inc. Common Stock shares in Q4 2024, an estimated $20M.
  • Morgan Stanley first reported a position in Axonics, Inc. Common Stock in Q4 2018 and held it in 24 quarters.
  • Morgan Stanley's Axonics, Inc. Common Stock position peaked at $27.2M in Q1 2023.
  • 2 funds tracked by Wall St. Rank held Axonics, Inc. Common Stock as of Q4 2024.

Based on Morgan Stanley's 13F filing for Q4 2024, filed 14 Feb 2025.